Heparin

Human Platelet Lysate Market Set for Healthy Growth Prospects; Clinical Application Account for 90% of Demand, Says Persistence Market Research

Retrieved on: 
Wednesday, March 11, 2020
Branches of biology, Blood, Transfusion medicine, Growth factors, Coagulation system, In science, Platelet, Heparin, Epidermal growth factor

Favorable government regulations and upsurge in R&D investments are also bolstering the market growth, according to a new Persistence Market Research (PMR) report.

Key Points: 
  • Favorable government regulations and upsurge in R&D investments are also bolstering the market growth, according to a new Persistence Market Research (PMR) report.
  • Heparin-free platelet lysates and human platelet lysates will remain the preferred types in market.
  • North America continues to lead the global human platelet lysate market, with concentration of established research institutes in the region.
  • Soaring bacterial and viral infection cases would enhance the scope of application for human platelet lysates, generating growth opportunities in market.

Meitheal Pharmaceuticals Announces FDA Approval of Additional Manufacturing Capacity and Future Facility Expansion Plans for Production of Heparin Sodium Injection, USP

Retrieved on: 
Tuesday, February 11, 2020
FDA, General Health, Pharmaceutical, Health, Health, Food and Drug Administration, United States Public Health Service, Heparin, Articles

This approval doubles Meitheals FDA-approved vial capacity to supply the US market with planned expansion expected to further increase Meitheals supply capacity.

Key Points: 
  • This approval doubles Meitheals FDA-approved vial capacity to supply the US market with planned expansion expected to further increase Meitheals supply capacity.
  • The new line and future expansion plans (10 total manufacturing lines) supports Meitheals majority shareholder, NKFs commitment to ensuring capacity to supply the US market for years to come.
  • Construction of a second Nanjing, China facility, which is currently underway, will have 4 additional manufacturing lines.
  • Meitheal is NKFs exclusive commercialization arm for the US market, ensuring consistent and dedicated supply of heparin.

Diagnostica Stago Inc, Product Pipeline Analysis 2019 Update: Venoms, Activators, Purified Proteins, Coagulation Factors, Inhibitors, Chromogenic Substrates, Lupus Inhibitors & Heparin Anti-Xa Assays - ResearchAndMarkets.com

Retrieved on: 
Monday, January 20, 2020
Medical devices, Health, Coagulation system, Branches of biology, Proteins, Blood tests, RTT, Acute phase proteins, Blood, Coagulation, Fibrin degradation product, Substrate, Fibrinogen, Heparin

The "Diagnostica Stago Inc - Product Pipeline Analysis, 2019 Update" company profile has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diagnostica Stago Inc - Product Pipeline Analysis, 2019 Update" company profile has been added to ResearchAndMarkets.com's offering.
  • Diagnostica Stago Inc (Stago), a subsidiary of Diagnostica Stago SAS, is a medical device company that develops and distributes in-vitro diagnostic products.
  • Stago's research and reagent products includes venoms, activators, purified proteins, coagulation factors, inhibitors, chromogenic substrates, lupus inhibitors, heparin anti-xa assays, coagulation inhibitors, fibrin and fibrinogen degradation products, among others.
  • This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products.

Hikma launches prefilled syringes in the US

Retrieved on: 
Tuesday, September 17, 2019
Chemistry, RTT, Organic compounds, Drugs, Pharmaceutical industry, Medical equipment, Hikma, Syringe, Heparin, Pharmacy, Heroin, Medication

"Our Heparin Sodium Injection prefilled syringes are ready-to-administer and will help hospitals, pharmacists, doctors and nurses treat patients faster, more easily and with reduced risk.

Key Points: 
  • "Our Heparin Sodium Injection prefilled syringes are ready-to-administer and will help hospitals, pharmacists, doctors and nurses treat patients faster, more easily and with reduced risk.
  • "Hikma is continuously expanding its broad and deep portfolio of essential injectable medicines" said Riad Mishlawi, President, Hikma Injectables.
  • Today one in every six injectable generic medicines used in US hospitals is a Hikma product.
  • Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world.

Aniara Diagnostica Launches hit-assay.Com Providing Specific Products for Detection of Heparin Induced Thrombocytopenia

Retrieved on: 
Friday, November 23, 2018
Medicine, Immunology, Health, Glycoproteins, Heparins, Immunologic tests, Immune system, Heparin, Antibody, ELISA, Immunoglobulin G, Isotype

Recently the company announced a new site hit-assay.com which highlights the availability of standardized ELISA Methods for the detection of Heparin-dependent antibodies.

Key Points: 
  • Recently the company announced a new site hit-assay.com which highlights the availability of standardized ELISA Methods for the detection of Heparin-dependent antibodies.
  • Enzyme Immuno-assay (HIT) designed for measuring Heparin-dependent antibodies of the IgG isotype, in human plasma.
  • Aniara distributes Hyphen BioMed's entire line of diagnostic and research reagents for Thrombosis, Hemostasis, and Autoimmunity.
  • The Company distributes products in North America, Central America, South America, Sweden, Norway, Denmark, Finland, Lithuania, Latvia, Estonia and Iceland.